Research into new diagnostic approaches for DR-TB.
The TriAD study aims to assess the effectiveness, feasibility, acceptability, and cost effectiveness of the GeneXpert MTB/XDR assay for rapid triage-and-treatment of DR-TB. The TriAD study is operating in Ethiopia, Nigeria and South Africa. KNCV is part of the study consortium, led by the Centre for the AIDS Program of Research in South Africa (“CAPRISA”), and supports the study in Ethiopia. Thus far KNCV has enrolled 28 patients from 5 hospitals in the study.
KNCV also developed a study protocol to assess the feasibility and acceptability (amongst healthcare staff) of the TriAD approach. This protocol will undergo ethical review in early 2023.